Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice-Reference-Cited by-同舟云学术

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice

Published:2019-03-25 Issue:6 Volume:145 Page:1613-1623
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Ahn Beung-Chul,Pyo Kyoung-Ho,Xin Chun-Feng,Jung Dongmin,Shim Hyo Sup,Lee Chang Young,Park Seong Yong,Yoon Hong In,Hong Min Hee,Cho Byoung Chul,Kim Hye Ryun

Funder

National Research Foundation of Republic of Korea

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-019-02899-y.pdf

Reference33 articles.

1. Borghaei H et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

2. Brahmer J et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627

3. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (2018) https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . Accessed 31 Jan 2018

4. Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

5. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886–894. https://doi.org/10.1158/1078-0432.Ccr-15-1136

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Camrelizumab-induced anaphylactic reaction: a case report and literature review;Journal of Chemotherapy;2024-06-27

3. Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis;Frontiers in Oncology;2024-05-08

4. Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan;Frontiers in Oncology;2024-04-30

5. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation;Archives of Pathology & Laboratory Medicine;2024-04-16